复发晚期胸腺上皮肿瘤患者的新兴治疗选择
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.
作者信息
Evans Tracey L
机构信息
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Onco Targets Ther. 2012;5:177-84. doi: 10.2147/OTT.S23267. Epub 2012 Sep 7.
Abstract
The purpose of this review article is to review recent advances in the treatment of advanced thymic epithelial tumors. These tumors are generally responsive to cytotoxic combination chemotherapy in the first-line setting. While newer agents have shown efficacy in the salvage setting, there is no one standard approach. A multitude of targeted agents have shown promise generally in case reports, though as of yet, nothing has shown consistent benefit. Because of the rarity of thymic epithelial tumors, clinical trial enrollment is difficult but nevertheless essential.
摘要
这篇综述文章的目的是回顾晚期胸腺上皮肿瘤治疗的最新进展。这些肿瘤在一线治疗中通常对细胞毒性联合化疗有反应。虽然新型药物在挽救治疗中已显示出疗效，但尚无统一的标准方法。许多靶向药物在病例报告中总体上显示出前景，不过截至目前，尚无药物显示出持续的益处。由于胸腺上皮肿瘤罕见，临床试验入组困难，但仍然至关重要。
相似文献
1
Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.复发晚期胸腺上皮肿瘤患者的新兴治疗选择
Onco Targets Ther. 2012;5:177-84. doi: 10.2147/OTT.S23267. Epub 2012 Sep 7.
2
[Chemotherapy for thymic carcinoma].[胸腺癌的化疗]
Gan To Kagaku Ryoho. 2012 May;39(5):702-7.
3
The role of targeted therapy in thymic carcinoma.靶向治疗在胸腺癌中的作用。
J Oncol Pharm Pract. 2019 Oct;25(7):1712-1718. doi: 10.1177/1078155219852758. Epub 2019 Jun 4.
4
Systemic treatment of advanced thymic malignancies.晚期胸腺恶性肿瘤的全身治疗。
Am Soc Clin Oncol Educ Book. 2014:e367-73. doi: 10.14694/EdBook_AM.2014.34.e367.
5
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.胸腺瘤的靶向治疗：新的前景？文献综述及两例病例报告
Future Oncol. 2015;11(8):1223-32. doi: 10.2217/fon.14.318.
6
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma.胸腺癌化疗与药物治疗的未来展望
Cancers (Basel). 2021 Oct 19;13(20):5239. doi: 10.3390/cancers13205239.
7
Treatment updates in advanced thymoma and thymic carcinoma.晚期胸腺瘤和胸腺癌的治疗进展。
Curr Treat Options Oncol. 2012 Dec;13(4):527-34. doi: 10.1007/s11864-012-0211-7.
8
[Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)].《胸腺上皮肿瘤临床诊疗中国专家共识（2021年版）》
Zhonghua Zhong Liu Za Zhi. 2021 Apr 23;43(4):395-404. doi: 10.3760/cma.j.cn112152-20210313-00226.
9
Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level.培美曲塞方案治疗复发晚期胸腺上皮肿瘤的疗效及其与胸苷酸合成酶水平的关系。
Onco Targets Ther. 2016 Jul 22;9:4527-31. doi: 10.2147/OTT.S105949. eCollection 2016.
10
Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.根据 2004 年世界卫生组织标准分期的晚期或复发性胸腺瘤上皮性肿瘤患者接受奥曲肽和泼尼松治疗后的表皮生长因子受体、C-kit 和 Her2/neu 免疫组化：东部肿瘤协作组研究。
J Thorac Oncol. 2010 Jun;5(6):885-92. doi: 10.1097/JTO.0b013e3181d86a30.
引用本文的文献
1
The clinical features, diagnosis and management of recurrent thymoma.复发性胸腺瘤的临床特征、诊断与治疗
J Cardiothorac Surg. 2016 Aug 31;11(1):140. doi: 10.1186/s13019-016-0533-9.
本文引用的文献
1
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.一项评估口服每日一次沙卡替尼（AZD0530，一种Src 抑制剂）治疗晚期胸腺癌患者的 II 期研究。
Lung Cancer. 2015 Jul;89(1):57-60. doi: 10.1016/j.lungcan.2015.04.008. Epub 2015 Apr 25.
2
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.激活一组胸腺癌中的 c-KIT 突变和对不同 c-KIT 抑制剂的反应。
Ann Oncol. 2012 Sep;23(9):2409-2414. doi: 10.1093/annonc/mdr626. Epub 2012 Feb 21.
3
Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.卡铂和紫杉醇联合化疗治疗晚期胸腺癌。
Jpn J Clin Oncol. 2011 Aug;41(8):1013-6. doi: 10.1093/jjco/hyr089. Epub 2011 Jul 7.
4
Imatinib mesylate in thymic epithelial malignancies.甲磺酸伊马替尼治疗胸腺瘤上皮性肿瘤。
Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2011 Jun 28.
5
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.贝林司他治疗复发性或难治性晚期胸腺癌患者的 II 期研究。
J Clin Oncol. 2011 May 20;29(15):2052-9. doi: 10.1200/JCO.2010.32.4467. Epub 2011 Apr 18.
6
[A case of recurrent invasive thymic cancer showing a stable disease to carboplatin plus paclitaxel].
Gan To Kagaku Ryoho. 2010 Nov;37(11):2161-3.
7
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.索拉非尼治疗伴有 C-KIT 外显子 11 缺失突变的复发性胸腺癌的疗效确切。
Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.
8
The role of chemotherapy in advanced thymoma.胸腺癌的化疗作用。
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S357-60. doi: 10.1097/JTO.0b013e3181f21129.
9
Thymic tumors: relevant molecular data in the clinic.胸腺肿瘤：临床相关的分子数据。
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S291-5. doi: 10.1097/JTO.0b013e3181f209b9.
10
Thymoma and thymic carcinoma: molecular pathology and targeted therapy.胸腺瘤和胸腺癌：分子病理学与靶向治疗。
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S286-90. doi: 10.1097/JTO.0b013e3181f209a8.
Zotero 插件